Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.

Autor: Socié G; Hôpital Saint-Louis, Paris, France., Barba P; Hospital Universitari Vall Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Barlev A; Atara Biotherapeutics, Thousand Oaks, CA, USA. abarlev@atarabio.com., Sanz J; Hospital Universitari I Politècnic La Fe, Valencia, Spain., García-Cadenas I; Hematology Division, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain., Chevallier P; CHU Hotel Dieu, Nantes, France., Fagioli F; Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy.; University of Turin, Turin, Italy., Guzman-Becerra N; Atara Biotherapeutics, Thousand Oaks, CA, USA., Kumar D; Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada., Ljungman P; Karolinska Institutet Huddinge, Stockholm, Sweden.; Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden., Pigneux A; CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France., Sadetsky N; Atara Biotherapeutics, Thousand Oaks, CA, USA., Yáñez San Segundo L; Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain., Shadman M; University of Washington, Seattle, WA, USA.; Fred Hutchinson Cancer Center, Seattle, WA, USA., Storek J; University of Calgary, Calgary, AB, Canada., Thirumalai D; Atara Biotherapeutics, Thousand Oaks, CA, USA., Xing B; Atara Biotherapeutics, Thousand Oaks, CA, USA., Mohty M; Sorbonne University, Saint-Antoine Hospital, Paris, France.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Jan; Vol. 59 (1), pp. 52-58. Date of Electronic Publication: 2023 Oct 21.

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

Autor: Dharnidharka, V., Thirumalai, D., Jaeger, U., Zhao, W., Dierickx, D., Xun, P., Minga, P., Sawas, A., Sadetsky, N., Chauvet, P., Sundaram, E., Barlev, A., Zimmerman, H., Ralf Trappe

Publikováno v: Ralf Trappe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be8302a8fac9dea3560317dcf1fd2563
https://doi.org/10.1097/01.hs9.0000847296.83232.25

Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV ⁺ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.

Autor: Chaganti S; Centre for Clinical Haematology, University Hospital Birmingham, Birmingham, UK., Barlev A; Atara Biotherapeutics, South San Francisco, CA, USA., Caillard S; Department of Nephrology Transplantation, Strasbourg University Hospitals, Strasbourg, France., Choquet S; Department of Hematology, Hospitalier Pitié Salpétrière, Paris, France., Cwynarski K; Department of Haematology, University College Hospital, London, UK., Friedetzky A; Atara Biotherapeutics, Zug, Switzerland., González-Barca E; Department of Hematology, Institut Català d'Oncologia, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Sadetsky N; Atara Biotherapeutics, South San Francisco, CA, USA., Schneeberger S; Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria., Thirumalai D; Atara Biotherapeutics, 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, 91320, USA. dthirumalai@atarabio.com., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy., Trappe RU; Department of Hematology and Oncology, DIAKO Hospital Bremen, Bremen, Germany.

Publikováno v: Advances in therapy [Adv Ther] 2023 Mar; Vol. 40 (3), pp. 1267-1281. Date of Electronic Publication: 2023 Jan 21.

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.

Autor: Ton TGN; Genentech, Inc., South San Francisco, California., Pal N; Genentech, Inc., South San Francisco, California., Trinh H; Genentech, Inc., South San Francisco, California., Mahrus S; Genentech, Inc., South San Francisco, California., Bretscher MT; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Machado RJM; Roche Products, Welwyn Garden City, UK., Sadetsky N; Genentech, Inc., South San Francisco, California., Chaudhary N; Genentech, Inc., South San Francisco, California., Lu MW; Genentech, Inc., South San Francisco, California., Riely GJ; Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jul 01; Vol. 28 (13), pp. 2844-2853.

Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study.

Autor: Tawbi H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., To TM; Genentech, Inc., South San Francisco, California, USA., Bartley K; Genentech, Inc., South San Francisco, California, USA., Sadetsky N; Genentech, Inc., South San Francisco, California, USA., Burton E; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haydu L; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McKenna E; Genentech, Inc., South San Francisco, California, USA.

Publikováno v: Cancer medicine [Cancer Med] 2022 Jan; Vol. 11 (1), pp. 139-150. Date of Electronic Publication: 2021 Dec 07.